CIK 0002044950
Bambusa Therapeutics, Inc.
Sign in to watch- Ticker
- BBTX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- other
- EIN
- 992083913
- Phone
- (617) 848-6188
- Business address
- 22 BOSTON WHARF ROAD, FLOOR 7, BOSTON, MA
- Open-market buys, last 90 days
- $58,639,957
- in 3 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$58,639,957. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-02 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +2,335,109 | $16.00 | $37.4M | 5,933,787 |
| 2026-11-02 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +164,891 | $16.00 | $2.6M | 1,495,971 |
| 2026-11-02 | Salvia Investment GmbH 10% owner | Purchase | +375,000 | $16.00 | $6.0M | 9,264,301 |
| 2026-11-02 | Jeggle Helmut Wolfgang Director | Purchase | +375,000 | $16.00 | $6.0M | 9,264,301 |
| 2026-10-30 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +189,909 | $14.23 | $2.7M | 189,909 |
| 2026-10-30 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +263,911 | $14.92 | $3.9M | 453,820 |
Page 1 of 1 · 6 trades